Background Image
Previous Page  169 / 182 Next Page
Information
Show Menu
Previous Page 169 / 182 Next Page
Page Background

168

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

214

Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J,

Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the

treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Pain 1999; 79: 303-312.

215

Portenoy RK, Raffaeli W, Torres LM, Sitte T, Deka AC, Herrera IG, Wallace MS; Fentanyl

Nasal Spray Study 045 Investigators Group. Long-term safety, tolerability, and consisten-

cy of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tole-

rant patients. J Opioid Manag 2010; 6(5): 319-328.

216

Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of

fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin

J Pain 2006; 22(9): 805-811.

217

Portenoy RK. Treatment of temporal variations in chronic cancer pain. Seminars in

Oncology 1997; 5 (Suppl 16): S16-7-12.

218

Präambel der Satzung der Weltgesundheitsorganisation vom 22. Juli 1946; abgedruckt

in Deutsch/Spickhoff, Medizinrecht, 6. Auflage 2008 Rdnr. 1731.

219

Prommer E, Ficek B. Fentanyl transmucosal tablets: current status in the management

of cancer-related breakthrough pain. Patient Prefer Adherence 2012; 6: 465-75.

220

Radbruch L, Torres LM, Ellershaw JE, Gatti A, Luis Lerzo G, Revnic J, Taylor D. Long-term

tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough

cancer pain. Support Care Cancer 2012; 20(3): 565-573.

221

Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for

breakthrough pain in patients with cancer: a randomized, double-blind, placebo-cont-

rolled study. Ann Oncol 2010; 21(6): 1308-1314.

222

Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick

R, Howell J. Efficacy and long-term tolerability of sublingual fentanyl orally disinteg-

rating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;

25(12): 2877-2885.

223

Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, Pigni A, De Conno F. Decreases

in pain at rest and movement-related pain during zoledronic acid treatment in patients

with bone metastases due to breast or prostate cancer: a pilot study. Support Care in

Cancer 2007; 15: 1177-1184.

224

Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain

and analgesic consumption decrease after samarium infusion: a pilot study. Support

Care Cancer 2007; 15: 339-342.

225

Robert R, Brack A, Blakeney P, Villarreal C, Rosenberg L, Thomas C, Meyer WJ 3rd. A

double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and

oral morphine in pediatric patients undergoing burn dressing change and tubbing. J

Burn Care Rehabil 2003; 24(6): 351-355.

226

Rousseff RT, Sieonov S. Intralesional treatment in painful ri metastases. Palliative Medi-

cine 2004; 18: 259.

Literaturverzeichnis